PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

被引：38

作者：

Banerjee, Susana ^{[2
]}

Kaye, Stan ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Div Clin Studies, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Gynaecol Unit, Sutton SM2 5PT, Surrey, England

来源：

CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 06期

关键词：

PARP inhibitors; Ovarian cancer; BRCA; Olaparib; Endometrial; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; MUTANT-CELLS; TUMOR; MUTATIONS; CARCINOMA; FEATURES; DELETION; REPAIR;

D O I：

10.1007/s11912-011-0193-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.

引用

页码：442 / 449

页数：8

共 50 条

[1] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
Susana Banerjee
Stan Kaye
Current Oncology Reports, 2011, 13 : 442 - 449
[2] Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?
Gonzalez Martin, Antonio
LANCET ONCOLOGY, 2017, 18 (01): : 8 - 9
[3] The role of PARP inhibitors in BRCA mutated pancreatic cancer
Chi, Jeffrey
Chung, Su Yun
Parakrama, Ruwan
Fayyaz, Fatima
Jose, Jyothi
Saif, Muhammad Wasif
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
[4] PARP Inhibitors in Breast Cancer: BRCA and Beyond
Rios, Jorge
Puhalla, Shannon
ONCOLOGY-NEW YORK, 2011, 25 (11): : 1014 - 1025
[5] PARP inhibitors in cancer: moving beyond BRCA
Telli, Melinda L.
LANCET ONCOLOGY, 2011, 12 (09): : 827 - 828
[6] BRCA mutated ovarian carcinomas: genetic counseling and PARP inhibitors prescription
Gladieff, Laurence
Lyonnet, Dominique Stoppa
Lortholary, Alain
Leary, Alexandra
Genestie, Catherine
Ray-Coquard, Isabelle
BULLETIN DU CANCER, 2017, 104 : S16 - S23
[7] PARP Inhibition in HRR Gene-Mutated Metastatic Castration- Resistant Prostate Cancer
Dorff, Tanya B.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2025, 23 (02) : 90 - 92
[8] Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
Nicoletto, Maria Ornella
Baldoni, Alessandra
Cavallin, Francesco
Grego, Andrea
Falci, Cristina
Nardin, Margherita
Mammano, Enzo
Lai, Eleonora
Torri, Valter
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[9] Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley, Charlie
Miller, Rowan E.
Hollis, Robert L.
Ledermann, Jonathan A.
CURRENT OPINION IN ONCOLOGY, 2020, 32 (05) : 442 - 450
[10] BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients
Gari, Abdulrahim
Rawas, Ghufran
Mufti, Ahmad
Elemam, Omima
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES, 2021, 10 (03): : 33 - 49

← 1 2 3 4 5 →